A New Path to Medicine Company Reception May 16, 2022 Exhibit 99.1 Forward Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws.

The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” “opportunity,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements regarding: the potential therapeutic benefits of proteins derived from tRNA synthetase genes and our product candidates, including efzofitimod and ATYR2810, and development programs, including our NRP2 antibody program and our tRNA synthetase program; the ability to successfully advance our product candidates and undertake certain development activities (such as the initiation of clinical trials, clinical trial enrollment, the conduct of clinical trials and announcement of clinical results) and accomplish certain development goals, and the timing of such events; the potential market opportunity for our product candidates; our ability to receive regulatory approvals for, and commercialize, our product candidates; our ability to identify and discover additional product candidates; potential activities and payments under collaboration agreements; and the ability of our intellectual property portfolio to provide protection are forward-looking statements. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. These risks, uncertainties and other factors are more fully described in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and in our other filings. The forward-looking statements in this presentation speak only as of the date of this presentation and neither we nor any other person assume responsibility for the accuracy and completeness of any forward-looking statement. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We own various U.S. federal trademark applications and unregistered trademarks, including our company name. All other trademarks or trade names referred to in this presentation are the property of their respective owners. Solely for convenience, the trademarks and trade names in this presentation are referred to without the symbols ® and ™, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. 2 Efzofitimod: A Novel Mechanism to Treat Lung Inflammation and Fibrosis 3 Representative histology showing immune cell infiltrate and collagen content in a rat model of bleomycin induced lung fibrosis presented at the ATS annual meeting 2018.

Placebo treated Efzofitimod treated Healthy lung Inflammation Fibrosis Foundational Science: Novel Functions of Extracellular tRNA Synthetases 4 tRNA synthetases are secreted extracellularly and occur in novel forms which lose their canonical function Extracellular tRNA synthetase disruption (genetic/ autoimmune) is associated with disease in humans Validated synthetase platform is an engine for new protein therapeutics (e.g.

efzofitimod) and new target ID (e.g. NRP2)

Efzofitimod (ATYR1923, KRP-R120) A Novel Immunomodulator for Fibrotic Lung Disease Efzofitimod: First-in-Class Therapy for Fibrotic Lung Disease 6 MOA = mechanism of action

7 Efzofitimod Therapeutic Goal: Restore Immune Balance and Prevent Fibrosis First Efzofitimod Indication: Pulmonary Sarcoidosis Multisystem inflammatory disorder of unknown etiology, characterized by the formation of granulomas (clumps of immune cells) Lung affected in ~90% of all patients ~5x increased mortality in advanced disease SOC: corticosteroids; cytotoxic immunosuppressants; anti-TNFs – limited development pipeline High unmet need for treatments with improved safety and clinically established efficacy 8 SOC – standard of care; Culver e2019; Baughman 2016; Baughman 2006, Mana 1994; Viskum 1993; Nagai 1999; Judson 1993; Neville 1983; Israel 1986; Wijsenbeek 2019 Persistent or progressive disease in 30-50% 50-75% require treatment Large orphan population 10-30% develop fibrosis with 5-10% mortality

Efzofitimod (ATYR1923, KRP-R120) Results from Phase 1b/2a Study in Pulmonary Sarcoidosis Peter H. S. Sporn, M.D. Professor of Medicine (Pulmonary and Critical Care); Cell and Developmental Biology; and Medical Education Northwestern University Feinberg School of Medicine Phase 1b/2a Trial Design 10 FVC = Forced Vital Capacity; PFTs = Pulmonary Function Tests

Phase 1b/2a Inclusion / Exclusion Criteria Inclusion Histologically proven diagnosis of pulmonary sarcoidosis Stable treatment with 10 -25 mg/day oral corticosteroid oral immunomodulator allowed Symptomatic/active disease at baseline FVC ≥ 50% percent predicted MRC Dyspnea Scale score (>= 1) Exclusion Disease consistent with Lofgren's syndrome Treatment with biological immunomodulator such as tumor necrosis factor-alpha inhibitors Clinically significant cardiac, neurological, gastrointestinal, and/or renal sarcoidosis PH requiring vasodilator treatment 11 Phase 1b/2a Study Schema 12 (1) subtherapeutic dose

Phase 1b/2a Disposition mITT = randomized and dosed; *Defined as receiving at least 5 doses and having an end of study assessment Treated (mITT) Prematurely Discontinued Completed* Table 14.1.1.1 23Aug2021 13 Baseline Demographics and Disease Characteristics Generally Balanced 14

Monthly Dosing of Efzofitimod was Safe and Well-Tolerated No new or unexpected findings with repeat dosing No dose-response relationship observed Most frequent AEs were consistent with underlying disease: Cough, fatigue, wheezing No signal of immunogenicity No drug related SAEs No deaths 15 Safety population Dose-dependent Reduction in Steroid Utilization Compared with Placebo 58% overall steroid reduction from baseline and 22% relative reduction compared to placebo in steroid utilization post taper in the 5 mg/kg treatment group 33% of patients able to taper off of steroids completely in 5 mg/kg treatment group while controlling disease symptoms 16 D51-EOS; adjusted mean refers to least squares mean from ANCOVA adjusting for baseline steroid use

Dose-dependent Improvement in FVC % Predicted Compared to Placebo 17 Differences represent from MMRM adjusting for baseline FVC % Predicted, mean (95% CI)

Higher Efzofitimod Doses Show Trends of Improvement in FVC % Predicted 18 Dose-dependent Improvements in PFTs Over Time Compared with Placebo 19 PFTs = Pulmonary Function Tests; CFB = Change From Baseline Where is week 24 data?

Dose-dependent Symptom Improvements Compared with Placebo 20 *p<0.05 on difference between adjusted means from MMRM; Pbo = Placebo MCIDs: TDI - Witek 2003; LCQ – Raj 2009; FAS - de Kleijin 2011 (Negative score is better for Fatigue); KSQ Lung – Baughman 2021; KSQ Lung – Baughman 2021 = clinically meaningful improvement based on published MCID Dose-dependent Control of Key Disease and Inflammatory Biomarkers 21 Graphs represent fold change at Week 24 compared to Baseline IFNg IP-10 / CXCL10 MCP-1 / CCL2 IL-2Ra

Phase 1b/2a Data Supports Proof-of-Concept and Clinical Advancement Efzofitimod was safe and well-tolerated Strong suggestion of efficacy: Dose-response and consistent positive trends across key efficacy endpoints and multiple analysis populations Clinically meaningful symptom improvements in dyspnea, cough, fatigue and King’s Sarcoidosis scores Dose dependent control of inflammatory biomarkers confirms anti-inflammatory effect 22 Efzofitimod (ATYR1923, KRP-R120) Phase 3 EFZO-FIT™ Study Robert P. Baughman, M.D. Emeritus Professor of Medicine University of Cincinnati

Dose-dependent Reduction in Steroid Utilization Compared with Placebo 58% overall steroid reduction from baseline and 22% relative reduction compared to placebo in steroid utilization post taper in the 5 mg/kg treatment group 33% of patients able to taper off of steroids completely in 5 mg/kg treatment group while controlling disease symptoms 24 D51-EOS; adjusted mean refers to least squares mean from ANCOVA adjusting for baseline steroid use Dose-dependent Symptom Improvements Compared with Placebo 25 *p<0.05 on difference between adjusted means from MMRM; Pbo = Placebo MCIDs: TDI - Witek 2003; LCQ – Raj 2009; FAS - de Kleijin 2011 (Negative score is better for Fatigue); KSQ Lung – Baughman 2021; KSQ Lung – Baughman 2021 = clinically meaningful improvement based on published MCID

EFZO-FITTM : Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis 26 Trial Design 27 Still under discussion with Kyorin clinical team

Major Efficacy Endpoints Primary Endpoint Change from baseline in mean daily OCS dose post-taper Secondary Endpoints Annual rate of change in absolute value of FVC Percent change from baseline in mean daily OCS dose post-taper at Week 48 Change from baseline in KSQ-Lung score at Week 48 28 Key Inclusion / Exclusion Criteria Inclusion Adults ages 18-75, inclusive Diagnosis of pulmonary sarcoidosis for ≥6 months Requiring stable treatment with ≥7.5 but ≤25 mg/day oral corticosteroids Medical Research Council (MRC) Dyspnea Scale ≥ 1 KSQ Lung Score ≤ 70 Exclusion Extent of fibrosis > 20% Forced Vital Capacity < 50% Treatment > 1 oral immunomodulator Clinically significant pulmonary hypertension Patients with cardiac/neuro/renal sarcoidosis Treatment with biological immunomodulators 29

Phase 3 Study Schema 30 OCS = oral corticosteroids Multi-center Trial with Sites in North America, Europe and Japan 31 Anticipating 60-80 centers in 10 countries

Thank You